0.8546

1.24% 0.0105

Oncolytics Biotech Inc (ONCY)

Overview News Price History Why ONCY Down? Discussions Forecast Stock Split

Oncolytics Biotech Inc stock is traded at $0.8546, with a volume of 273.87K. It is up +1.24% in the last 24 hours and up +5.22% over the past month. Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Previous Close:

$0.8441

Open:

$0.85

24h Volume:

273.87K

Relative Volume:

0.21

Market Cap:

$108.97M

Revenue:

Net Income/Loss:

$-25.91M

P/E Ratio:

-3.3951

EPS:

-0.2517

Net Cash Flow:

$-22.73M

1W Performance:

+1.16%

1M Performance:

+5.22%

6M Performance:

-23.01%

1Y Performance:

-13.57%

1-Day Range:

$0.8401

$0.8673

1-Week Range:

$0.7901

$0.8673

52-Week Range:

$0.7301

$1.51

Oncolytics Biotech Inc Stock (ONCY) Company Profile

Name

Oncolytics Biotech Inc

Sector

Healthcare (1083)

Industry

Biotechnology (582)

Phone

(403) 670-7377

Address

SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB

Employee

Twitter

@oncolytics

Next Earnings Date

2026-08-14

Latest SEC Filings

ONCY's Discussions on Twitter

Compare ONCY vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ONCY Oncolytics Biotech Inc	0.8546	102.23M	0	-25.91M	-22.73M	-0.2517
VRTX Vertex Pharmaceuticals Inc	551.96	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	833.88	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,024.54	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	155.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	214.10	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-13-25	Initiated	Lake Street	Buy
Oct-06-22	Initiated	Maxim Group	Buy
Feb-17-21	Initiated	H.C. Wainwright	Buy

Oncolytics Biotech Inc Stock (ONCY) Latest News

Aug 21, 2026

Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat

Aug 19, 2026

H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada

Aug 19, 2026

H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo

Aug 19, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 19, 2026

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - Yahoo Finance

Aug 19, 2026

Aug 18, 2026

BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget

Aug 18, 2026

Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus

Aug 18, 2026

Oncolytics Biotech Inc - Baystreet.ca

Aug 18, 2026

Stocks in play: Oncolytics Biotech Inc - Barchart.com

Aug 18, 2026

Form 8K Oncolytics Biotech Inc. For: 18 August By Investing.com - Investing.com Nigeria

Aug 18, 2026

Oncolytics receives FDA feedback on colorectal cancer study design - Investing.com

Aug 18, 2026

Oncolytics receives FDA feedback on colorectal cancer study design By Investing.com - Investing.com Canada

Aug 18, 2026

Oncolytics aligns with FDA on potential pivotal expansion of REO 033 in RAS‑mutant MSS colorectal cancer - TradingView

Aug 18, 2026

Oncolytics may seek accelerated approval using tumor response data - Stock Titan

Aug 18, 2026

Oncolytics Biotech (ONCY) 10K Form and Latest SEC Filings 2026 - MarketBeat

Aug 18, 2026

Aug 17, 2026

ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits

Aug 17, 2026

Aug 16, 2026

Oncolytics Biotech (ONCY) Climbs 4.25% to $0.83 as Small-Cap Biotech Finds BuyersRetracement Entry - vinanet.vn

Aug 16, 2026

Aug 15, 2026

ONCY Q3 2025 Earnings: Wider Loss Misses Estimates, Stock Still Rises 4.25%Cost Structure Review - vinanet.vn

Aug 15, 2026

Aug 14, 2026

ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill

Aug 14, 2026

Aug 13, 2026

Oncolytics Biotech (ONCY) Holds Near $0.82 as Shares Edge Up 0.49%Entry Point Alerts - vinanet.vn

Aug 13, 2026

Aug 12, 2026

Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

Aug 12, 2026

ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources - TradingView

Aug 12, 2026

Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 million - Bitget

Aug 12, 2026

Aug 10, 2026